Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study

James D. Chalmers (Lead / Corresponding author), Brian J. McHugh, Catherine Doherty, Maeve P. Smith, John R. Govan, David C. Kilpatrick, Adam T. Hill

    Research output: Contribution to journalArticle

    42 Citations (Scopus)

    Abstract

    Mannose-binding lectin (MBL) is a key component of innate immunity. MBL deficiency is common (10-30% of the general population depending on the definition used) and has been associated with disease progression in cystic fibrosis. We aimed to assess the effect of MBL deficiency on disease severity in non-cystic fibrosis bronchiectasis.
    Original languageEnglish
    Pages (from-to)224-232
    Number of pages9
    JournalThe Lancet Respiratory Medicine
    Volume1
    Issue number3
    DOIs
    Publication statusPublished - May 2013

    Fingerprint

    Deficiency Diseases
    Bronchiectasis
    Fibrosis
    Prospective Studies
    Mannose-Binding Lectin
    Innate Immunity
    Cystic Fibrosis
    Disease Progression
    Population
    Mannose-Binding Protein Deficiency

    Cite this

    Chalmers, James D. ; McHugh, Brian J. ; Doherty, Catherine ; Smith, Maeve P. ; Govan, John R. ; Kilpatrick, David C. ; Hill, Adam T. / Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis : a prospective study. In: The Lancet Respiratory Medicine. 2013 ; Vol. 1, No. 3. pp. 224-232.
    @article{6015fb40691b4ba2b8c88d7a553d2c32,
    title = "Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis: a prospective study",
    abstract = "Mannose-binding lectin (MBL) is a key component of innate immunity. MBL deficiency is common (10-30{\%} of the general population depending on the definition used) and has been associated with disease progression in cystic fibrosis. We aimed to assess the effect of MBL deficiency on disease severity in non-cystic fibrosis bronchiectasis.",
    author = "Chalmers, {James D.} and McHugh, {Brian J.} and Catherine Doherty and Smith, {Maeve P.} and Govan, {John R.} and Kilpatrick, {David C.} and Hill, {Adam T.}",
    note = "Copyright {\circledC} 2013 Elsevier Ltd. All rights reserved.",
    year = "2013",
    month = "5",
    doi = "10.1016/S2213-2600(13)70001-8",
    language = "English",
    volume = "1",
    pages = "224--232",
    journal = "The Lancet Respiratory Medicine",
    issn = "2213-2600",
    publisher = "Elsevier",
    number = "3",

    }

    Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis : a prospective study. / Chalmers, James D. (Lead / Corresponding author); McHugh, Brian J.; Doherty, Catherine; Smith, Maeve P.; Govan, John R.; Kilpatrick, David C.; Hill, Adam T.

    In: The Lancet Respiratory Medicine, Vol. 1, No. 3, 05.2013, p. 224-232.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Mannose-binding lectin deficiency and disease severity in non-cystic fibrosis bronchiectasis

    T2 - a prospective study

    AU - Chalmers, James D.

    AU - McHugh, Brian J.

    AU - Doherty, Catherine

    AU - Smith, Maeve P.

    AU - Govan, John R.

    AU - Kilpatrick, David C.

    AU - Hill, Adam T.

    N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.

    PY - 2013/5

    Y1 - 2013/5

    N2 - Mannose-binding lectin (MBL) is a key component of innate immunity. MBL deficiency is common (10-30% of the general population depending on the definition used) and has been associated with disease progression in cystic fibrosis. We aimed to assess the effect of MBL deficiency on disease severity in non-cystic fibrosis bronchiectasis.

    AB - Mannose-binding lectin (MBL) is a key component of innate immunity. MBL deficiency is common (10-30% of the general population depending on the definition used) and has been associated with disease progression in cystic fibrosis. We aimed to assess the effect of MBL deficiency on disease severity in non-cystic fibrosis bronchiectasis.

    U2 - 10.1016/S2213-2600(13)70001-8

    DO - 10.1016/S2213-2600(13)70001-8

    M3 - Article

    C2 - 24429128

    VL - 1

    SP - 224

    EP - 232

    JO - The Lancet Respiratory Medicine

    JF - The Lancet Respiratory Medicine

    SN - 2213-2600

    IS - 3

    ER -